XML 29 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Impairment of Fixed and Long-lived Assets
6 Months Ended
Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Impairment of Fixed and Long-lived Assets Impairment of Fixed and Long-lived Assets

During the first quarter 2020, the price of crude oil declined by over 50%, trading below $25 per barrel, causing a significant disruption across the industry, which began to negatively impact the Company’s results of operations. These declines of results of operations were driven by an oversupply of oil, insufficient storage, and demand destruction resulting from the reaction to COVID-19. Based on these factors, the Company concluded that a triggering event occurred and, accordingly, an interim quantitative impairment test was performed as of March 31, 2020.

Using the income approach, the fair value of the reporting unit was determined based on the present value of future cash flows. The Company utilized internal forecast trends and potential growth rates to estimate future cash flows of the asset group. Based on the results of the quantitative assessment, the Company concluded the carrying value of the asset group exceeded its fair value as of March 31, 2020 and an impairment loss of $57.5 million was recorded as a result of the adverse effect of the COVID-19 pandemic and the related negative impact on oil and natural gas prices on projections of future cash flows.

The Company recorded impairment charges during the six months ended June 30, 2020 as follows (in thousands):

Property and equipment, net
$
30,178

Operating lease right-of-use assets
7,434

 
 
Other Intangibles:
 
Patents
9,902

Customer Lists
9,165

Intangibles assets in progress
596

Trademarks and brand names
179

Total Other Intangibles
19,842

 
 
Total Impairment of fixed and long-lived assets
$
57,454



With the acquisition of JP3, the Company evaluated its segment information and determined that there were two segments: Chemistry Technologies and Data Analytics, which are both supported by its Research & Innovation advanced laboratory capabilities.